Quantitative proteomic determination of diethylstilbestrol action on prostate cancer.
暂无分享,去创建一个
O. Cussenot | P. Bigot | M. Bahut | K. Mouzat | N. Benhabilès | A. Azzouzi | S. Lebdai | G. C. Tassin
[1] M. Rouprêt,et al. Current role of diethylstilbestrol in the management of advanced prostate cancer , 2012, BJU international.
[2] R. Vessella,et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression , 2011, Oncogene.
[3] D. Gillatt,et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel , 2011, British Journal of Cancer.
[4] G. Rashid,et al. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells , 2010, The Prostate.
[5] S. Koochekpour,et al. Androgen receptor signaling and mutations in prostate cancer. , 2010, Asian journal of andrology.
[6] H. Miyake,et al. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. , 2010, Urologic oncology.
[7] J. Cuzick,et al. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement , 2009, British Journal of Cancer.
[8] Jo Vandesompele,et al. RTPrimerDB: the portal for real-time PCR primers and probes , 2008, Nucleic Acids Res..
[9] François G. Meyer,et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.
[10] P. Ekman,et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[11] P. Singh,et al. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. , 2008, European journal of cancer.
[12] W. Grody,et al. Expression of arginase II in prostate cancer. , 2008, International journal of oncology.
[13] L. Rejtõ,et al. Hormonal regulation of IGFBP‐2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model , 2007, Journal of cellular physiology.
[14] C. Ryan,et al. Diethylstilbestrol and docetaxel , 2007, Cancer.
[15] M. Sadar,et al. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. , 2006, Cellscience.
[16] Guanghui Wang,et al. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. , 2006, Journal of proteome research.
[17] T. Oyama,et al. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer , 2005, British Journal of Cancer.
[18] S. Bustin,et al. Evidence for a link between IGF-I and cancer. , 2004, European journal of endocrinology.
[19] W. Pitts,et al. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. , 2003, The Journal of urology.
[20] David C. Smith,et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma , 2003, Cancer.
[21] Ron D. Appel,et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..
[22] W. Oh. The evolving role of estrogen therapy in prostate cancer. , 2002, Clinical prostate cancer.
[23] S. Malkowicz. The role of diethylstilbestrol in the treatment of prostate cancer. , 2001, Urology.
[24] I. Leav,et al. Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .
[25] Guido Kroemer,et al. Hsp27 negatively regulates cell death by interacting with cytochrome c , 2000, Nature Cell Biology.
[26] J. Liehr,et al. Estrogens as endogenous genotoxic agents--DNA adducts and mutations. , 2000, Journal of the National Cancer Institute. Monographs.
[27] F. Chinegwundoh,et al. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone‐releasing hormone analogues and orchidectomy , 2000, BJU international.
[28] E. Solary,et al. HSP27 inhibits cytochrome c‐dependent activation of procaspase‐9 , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] S. Schwartz,et al. A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.
[30] K. Pienta,et al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. , 1998, Urology.
[31] H. Matsuzaki,et al. Activation of protein kinase B (Akt/RAC‐protein kinase) by cellular stress and its association with heat shock protein Hsp27 , 1997, FEBS letters.
[32] F. Guillé,et al. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma , 1996, Cancer.
[33] R. Fine,et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. , 1996, Journal of the National Cancer Institute.
[34] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[35] J. Boyle,et al. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. , 1993, Genomics.
[36] H. Pitot,et al. Transcriptional control of ornithine aminotransferase synthesis in rat kidney by estrogen and thyroid hormone. , 1984, The Journal of biological chemistry.
[37] P. McCann,et al. Polyamine metabolism and function. , 1982, The American journal of physiology.
[38] D. Byar. The veterans administration cooperative urological research group's studies of cancer of the prostate , 1973, Cancer.
[39] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.
[40] I. Leav,et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. , 2001, The American journal of pathology.
[41] Gary R. Grotendorst,et al. CCN proteins are distinct from and should not be considered members of the insulin-like growth factor-binding protein superfamily. , 2000, Endocrinology.
[42] D. Edwards,et al. Estrogen regulation of specific proteins as a mode of hormone action in human breast cancer. , 1983, Biomembranes.